European Medicines Agency recommends approval of first-in-class treatment for metastatic or unresectable melanoma

 

Novel protein-kinase inhibitor recommended for treatment of melanoma patients with BRAF V600 mutations

 

London, UK (December 16, 2011) – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a marketing authorisation for a novel protein-kinase inhibitor to treat patients suffering from metastatic or unresectable melanoma with BRAF V600 mutations.

 

Melanoma is the sixth most common malignancy in men and the seventh most common malignancy in women. In Europe, doctors diagnose almost 60,000 new cases of melanoma per year. Approximately 8,300 men and 7,600 women die from this type of cancer every year. When detected and treated early, patients with localised melanoma have an excellent prognosis, with a survival rate of more than 90%. However, for patients with unresectable or metastatic melanoma, the prognosis remains poor: it is estimated that only 25.5% of patients diagnosed with this type of disease are still alive one year after first diagnosis; five years after the first diagnosis, less than 15% of patients are still alive.

 

There is a high unmet medical need for alternative treatments for metastatic melanoma that improve survival of patients. In the pivotal clinical trial, Zelboraf (vemurafenib), the new protein-kinase inhibitor, was compared to the standard first-line treatment of dacarbazine. The medicine was shown to improve progression-free survival (PFS) by about 4 months (5.3 months for vemurafenib compared to 1.6 months for dacarbazine) and overall survival (OS) by about 3 months (13.2 months for vemurafenib compared to 9.9 months for dacarbazine) in patients who tested positive for BRAF V600 mutations.

 

In its assessment, the CHMP also looked at potential side effects of Zelboraf. The Committee considered that although there was a risk of secondary neoplasms, most notably squamous cell carcinoma of the skin (cuSCC), the magnitude of the risk was likely to be low. The Committee also noted that the applicant’s risk-management plan for this medicine detailed adequate risk-minimisation measures and the product information contained appropriate information so that cuSCC can be managed in clinical practice, e.g. by routine monitoring during treatment.

 

Following review of all available data, the Committee concluded during its December 2011 meeting that the benefits of Zelboraf, particularly the improvements seen in terms of PFS and OS of patients, outweigh its risks, and recommended that a marketing authorisation should therefore be granted.

 

 

Notes

 

  • The CHMP’s recommendation is now being sent to the European Commission for the adoption of a binding decision.
  • The review of Zelboraf began in May 2011, with an active review time by the CHMP of 180 days.

 

 


European Medicines Agency, 16.12.2011 (tB).

MEDICAL NEWS

Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds

SCHMERZ PAINCARE

Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern

DIABETES

Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…
Minimalinvasive Geräte warnen ungenügend vor Unterzuckerung
Typ-1-Diabetes und Hashimoto-Thyreoiditis treten häufig gemeinsam auf

ERNÄHRUNG

Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren

ONKOLOGIE

Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege
Sotorasib: Neues Medikament macht Lungenkrebs-Patienten Hoffnung

MULTIPLE SKLEROSE

NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen
Verzögerte Verfügbarkeit von Ofatumumab (Kesimpta®)
Neuer Biomarker bei Multipler Sklerose ermöglicht frühe Risikoeinschätzung und gezielte…
Multiple Sklerose beginnt oft lange vor der Diagnose
Goldstandard für Versorgung bei Multipler Sklerose

PARKINSON

Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung